Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01846208 · ClinicalTrials.gov registry record · Phase 2
Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy
A Phase 2 study of Food Allergy, sponsored by Hugh A Sampson, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 5
- Study locations
NCT01846208: Completed Phase 2 study of Food Allergy, sponsored by Hugh A Sampson, MD.
NCT01846208 is a Phase 2 study of Food Allergy that has completed, run by Hugh A Sampson, MD. The registered enrollment target is 92 participants, below the 959-participant average among 17 other Food Allergy trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01846208, a Phase 2 study of Food Allergy, has completed, sponsored by Hugh A Sampson, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to compare Baked Egg vs. Egg Oral Immunotherapy for inducing sustained unresponsiveness to egg exposure in children.
Primary Outcome
Sustained unresponsiveness - able to successfully consume 7444 mg egg white protein in a desensitization OFC and, after an 8-10 week egg-free interval, were also able to successfully consume 7444 mg egg white protein in an OFC after up to 2 years of therapy.
Conditions Studied
Interventions
- DRUG Egg Oral Immunotherapy
- DRUG Baked Egg
Study Locations (5)
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- National Jewish Health - Denver
Maryland
- Johns Hopkins University - Baltimore
New York
- Icahn School of Medicine at Mount Sinai - New York
North Carolina
- University of North Carolina - Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2013-07 |
| Est. Completion | 2018-09-30 |
| Phase | Phase 2 |
What the finished NCT01846208 record still lists
NCT01846208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 959-participant average among 17 other Food Allergy trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Food Allergy appearing as the primary indexed condition, and to 2 interventions - of which Egg Oral Immunotherapy is the first listed.
NCT01846208 lists 5 locations in 5 states (Arkansas, Colorado, Maryland).
Frequently Asked Questions
What is clinical trial NCT01846208 about?
NCT01846208 is a clinical study titled "Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy". The purpose of this study is to compare Baked Egg vs. Egg Oral Immunotherapy for inducing sustained unresponsiveness to egg exposure in children.
What is the current status of trial NCT01846208?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2013-07. Estimated completion is 2018-09-30.
What conditions does trial NCT01846208 study?
This clinical trial studies the following conditions: Food Allergy.
What interventions are being tested in trial NCT01846208?
The interventions under investigation include: Egg Oral Immunotherapy (DRUG), Baked Egg (DRUG).
Who is sponsoring clinical trial NCT01846208?
This trial is sponsored by Hugh A Sampson, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01846208 being conducted?
This trial has 5 study locations across Arkansas, Colorado, Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01846208's enrollment target sits among peer trials
92 7th of 17 higher than 11 of 17 other Food Allergy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Food Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Omalizumab Weight-Based Dosing Efficacy Trial
RECRUITING · Phase 2
-
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
COMPLETED · Phase 2
-
Multi Immunotherapy to Test Tolerance and Xolair
COMPLETED · Phase 2
-
Preventing Anaphylaxis With Acalabrutinib
COMPLETED · Phase 2
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia